首页 > 市场调查报告书 > 製药

生物製剂分子标靶治疗学

市场调查报告书

商品编码

1358031

抗体药物复合体(ADC) 市场：按产品类型、按接头类型、按用途、按配销通路、按地区

Antibody Drug Conjugates Market, By Product Type, By Linker Type, By Application, By Distribution Channel, By Geography

出版日期: 2023年09月12日 | 出版商:

Coherent Market Insights | 英文 210 Pages | 商品交期: 2-3个工作天内

价格

简介目录

预计2023年全球抗体药物复合体（ADC）市场规模为53.8亿美元，预计2030年将达到136.5亿美元，在预测期间（2023-2030年）成长潜力巨大，年复合成长率为14.2%。

报告范围		报告详情
基准年	2022年	2023年市场规模	53.8亿美元
实绩资料	2018-2021	预测期	2023-2030
预测期年复合成长率	14.20%	2030年市场规模预测	136.5亿美元

抗体药物复合体(ADC)全球市场占有率(%)（依产品类型），2023 年

抗体药物复合体(ADC) 通常是透过化学接头与细胞毒性药物共用的单株抗体 (mAb)。 ADC结合了高特异性标靶能力和强杀伤作用的优点，能够准确、有效率地消灭癌细胞，已成为抗癌药物研发的热点之一。自2000年美国食品药物管理局（FDA）核准第一个ADC帕多塞布（吉妥珠单抗奥佐米星）以来，全球已有14个ADC核准。此外，超过 100 种 ADC 候选药物目前正在临床阶段进行研究。抗体药物复合体(ADC) 透过稳定的生物分解性接头将高效细胞毒性抗癌药物附着到单株抗体上，以区分癌症和正常组织。这些接头可以是可裂解的或不可裂解的。连接体技术需要进步，将单株抗体与细胞毒性抗癌药物结合、控制药物药物药物动力学，并大幅改善细胞毒性药物向癌细胞的传递。抗体标靶将标靶抗体-药物缀合物与特定肿瘤抗原特异性结合，内化抗原-抗体复合物，并将标靶化疗。

市场动态

用于癌症治疗的新型 ADC 候选药物的核准预计将支持预测期内的市场成长。例如，2023年2月3日，製药公司吉利德科学公司获得美国食品药物管理局（FDA）批准，用于治疗荷尔蒙受体（HR）阳性、人类表皮生长因子受体2（HER2）阴性患者无法手术的局部治疗宣布核准Trodelvy (sacituzumab govitecan-hziy) 用于治疗成年进行性或转移性乳癌患者（IHC 0、IHC 1+ 或 IHC 2+/ISH-）。这些患者必须在转移期之前接受过内分泌治疗和至少两次额外的全身性治疗。

本次测试的主要特点

本报告对全球抗体药物复合体（ADC）市场进行了详细分析，并提出了以2022年为基准年的预测期（2023-2030）的市场规模和復合年度（年复合成长率）。
它还强调了各个细分市场的潜在收入成长机会，并为该市场说明了一系列有吸引力的投资提案。
它还提供了有关市场促进因素、抑制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要考察。
根据公司亮点、产品系列、主要亮点、绩效和策略等参数对全球抗体药物复合体(ADC) 市场的主要企业进行了分析。
该报告的见解使行销人员和公司负责人能够就未来的产品发布、产品类型升级、市场扩张和行销策略做出资讯的决策。
本研究报告针对该产业的各个相关人员，如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
透过用于分析全球抗体药物复合体（ADC）市场的各种策略矩阵，将有助于相关人员做出决策。

公司简介
- AstraZeneca PLC
- Daiichi Sankyo Company, Limited
- Novasep
- ADC Therapeutics SA
- Alentis Therapeutics AG
- F. Hoffmann-La Roche
- Gilead Sciences, Inc.
- AbbVie Inc.
- Biosion USA, Inc.
- Astellas Pharma Inc.
- Duality Biologics（Suzhou）Co. Ltd.
- BioNTech SE
- LaNova Medicines Ltd.
- Bliss Biopharmaceutical
- Eisai Co., Ltd.
- ProfoundBio
- Pfizer, Inc.
- ImmunoGen Inc.
- Mersana Therapeutics Inc.
- Sorrento Therapeutics Inc.
- Oxford BioTherapeutics Ltd
- Takeda Pharmaceutical Company Ltd

第11章章节

参考
调查方法

简介目录

Product Code: CMI181

The global antibody drug conjugates market is estimated to be valued at US$ 5.38 billion in 2023 and is expected to reach US$ 13.65 billion by 2030, exhibiting a CAGR of 14.2% during the forecast period (2023-2030).

Report Coverage		Report Details
Base Year:	2022	Market Size in 2023:	US$ 5.38 Bn
Historical Data for:	2018 to 2021	Forecast Period:	2023 - 2030
Forecast Period 2023 to 2030 CAGR:	14.20%	2030 Value Projection:	US$ 13.65 Bn

Global Antibody Drug Conjugates Market Share (%), By Product Type, 2023

Antibody Drug Conjugate (ADC) is typically made up of a monoclonal antibody (mAb) covalently attached to a cytotoxic drug via a chemical linker. It combines the advantages of highly specific targeting ability and a highly potent killing effect to achieve accurate and efficient elimination of cancer cells, making it one of the hotspots for anticancer drug research and development. Since the approval of the first ADC, Padcev (gemtuzumab ozogamicin) in 2000 by the U.S. Food and Drug Administration (FDA), till now 14 ADCs have been approved for market use worldwide. Furthermore, over 100 ADC candidates are currently being studied in clinical stages. Antibody-drug conjugates attach highly potent cytotoxic anticancer agents to monoclonal antibodies via biodegradable, stable linkers and discriminate between cancer and normal tissue. These linkers are either cleavable or non-cleavable. Linker technology advancements are required to attach monoclonal antibodies to cytotoxic anticancer agents, allowing control over drug pharmacokinetics and significantly improving cytotoxic agent delivery to cancer cells. The specific binding of the targeting antibody-drug conjugate to the specific tumor antigen and the internalization of the antigen-antibody complex to ensure focused delivery of the conjugated cytotoxic agent inside tumor cells are critical to the efficacy of antibody-targeted chemotherapy.

Market Dynamics

Approvals of novel ADC candidates for the treatment of cancer are anticipated to support the market growth over the forecasted period. For instance, on February 3, 2023, Gilead Sciences, Inc., a pharmaceutical firm, announced that the U.S. Food and Drug Administration (FDA) granted approval for Trodelvy (sacituzumab govitecan-hziy) to be used in treating adult patients afflicted with inoperable locally advanced or metastatic breast cancer that is hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+, or IHC 2+/ISH-). These patients should have previously undergone endocrine-based therapy and received a minimum of two additional systemic therapies in the metastatic phase.

Key features of the study:

This report provides an in-depth analysis of the global antibody drug conjugates market and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global antibody drug conjugates market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
The key companies covered as a part of this study include AstraZeneca PLC, Daiichi Sankyo Company, Limited, Novasep, ADC Therapeutics SA, Alentis Therapeutics AG, F. Hoffmann-La Roche, Gilead Sciences, Inc., AbbVie Inc., Biosion USA, Inc., Astellas Pharma Inc., Duality Biologics (Suzhou) Co. Ltd., BioNTech SE, LaNova Medicines Ltd., Bliss Biopharmaceutical, Eisai Co., Ltd., ProfoundBio, Pfizer, Inc., ImmunoGen Inc., Mersana Therapeutics Inc., Sorrento Therapeutics Inc., Oxford BioTherapeutics Ltd, and Takeda Pharmaceutical Company Ltd.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global antibody drug conjugates market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global antibody drug conjugates market

Detailed Segmentation:

By Product Type:
- Adcetris
- Kadcyla
- Enhertu
- Trodelvy
- Padcev
- Others (Blenrep, Tivdak, Zynlota, Elahere, etc.)
By Linker Type:
- Non-cleavable Linker
- Cleavable Linker
By Application:
- Blood Cancer
- Breast Cancer
- Ovary Cancer
- Lung Cancer
- Skin Cancer
- Brain Tumor
- Others (Renal Caner, Urothelial & Bladder Cancer, etc.)
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- E-commerce
By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles
- AstraZeneca PLC
- Daiichi Sankyo Company, Limited
- Novasep
- ADC Therapeutics SA
- Alentis Therapeutics AG
- F. Hoffmann-La Roche
- Gilead Sciences, Inc.
- AbbVie Inc.
- Biosion USA, Inc.
- Astellas Pharma Inc.
- Duality Biologics (Suzhou) Co. Ltd.
- BioNTech SE
- LaNova Medicines Ltd.
- Bliss Biopharmaceutical
- Eisai Co., Ltd.
- ProfoundBio
- Pfizer, Inc.
- ImmunoGen Inc.
- Mersana Therapeutics Inc.
- Sorrento Therapeutics Inc.
- Oxford BioTherapeutics Ltd
- Takeda Pharmaceutical Company Ltd

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Linker Type
- Market Snippet, By Application
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Recent Product Launches
Epidemiology
Merger, Acquisition, and Collaborations
Regulatory Scenario
Key Developments
PEST Analysis

4. Global Antibody Drug Conjugates Market - COVID-19 Impact Analysis

Economic Impact
COVID-19 Epidemiology
Impact on Supply and Demand

5. Global Antibody Drug Conjugates Market, By Product Type, 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Adcetris
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Kadcyla
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Besponsa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Lumoxiti
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Mylotarg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Others (Polivy, Lumoxiti, Zynlonta, etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends

6. Global Antibody Drug Conjugates Market, By Linker Type, 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Non-Cleavable Linker
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends
Cleavable Linker
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
- Segment Trends

7. Global Antibody Drug Conjugates Market, By Application, 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Blood Cancer
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Breast Cancer
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Ovary Cancer
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Lung Cancer
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Skin Cancer
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Brain Tumor
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Others
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends

8. Global Antibody Drug Conjugates Market, By Distribution Channel , 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)
E-commerce
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2018 - 2030, (US$ Bn)

9. Global Antibody Drug Conjugates Market, By Region, 2018 - 2030, (US$ Bn)

Introduction
- Market Share Analysis, 2023 and 2030 (%)
- Y-o-Y Growth Analysis, 2018 - 2030
- Segment Trends
North America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2018 - 2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
U.S.
Canada
Europe
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2018 - 2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2018 - 2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2018 - 2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
Brazil
Mexico
Argentina
Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2018 - 2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
GCC
Israel
Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, Y-o-Y Growth and By Product Type, 2018 -2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Linker Type, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Application, 2018 - 2030, (US$ Bn)
- Market Size and Forecast, Y-o-Y Growth and By Distribution Channel , 2018 - 2030, (US$ Bn)
- Market Size and Forecast, By Country, Y-o-Y Growth and By Country, 2018 - 2030, (US$ Bn)
North Africa
Central Africa
South Africa

10. Competitive Landscape

Company Profiles
- AstraZeneca PLC
Company Overview
Product Portfolio
Key Highlights
Financial Overview
Strategies
- Daiichi Sankyo Company, Limited
- Novasep
- ADC Therapeutics SA
- Alentis Therapeutics AG
- F. Hoffmann-La Roche
- Gilead Sciences, Inc.
- AbbVie Inc.
- Biosion USA, Inc.
- Astellas Pharma Inc.
- Duality Biologics (Suzhou) Co. Ltd.
- BioNTech SE
- LaNova Medicines Ltd.
- Bliss Biopharmaceutical
- Eisai Co., Ltd.
- ProfoundBio
- Pfizer, Inc.
- ImmunoGen Inc.
- Mersana Therapeutics Inc.
- Sorrento Therapeutics Inc.
- Oxford BioTherapeutics Ltd
- Takeda Pharmaceutical Company Ltd